Pretreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

Subjects:

Unique intestinal microbiota in healthy shrimp. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Taxa bar plot of intestinal microbiota from healthy and diseased shrimp at the genus level. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Taxa bar plot of intestinal microbiota from healthy and diseased shrimp at the class level. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Functional feature prediction of intestinal microbiota from healthy (blue) and diseased (orange) shrimp. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Taxa bar plot of intestinal microbiota from healthy and diseased shrimp at the phylum level. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Venn diagram based on ASVs of intestinal microbiota from healthy and diseased shrimp. by Lalitphan Kitsanayanyong (19353505)

Subjects:

β-diversity of intestinal microbiota from healthy and diseased shrimp. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Unique intestinal microbiota in diseased shrimp. by Lalitphan Kitsanayanyong (19353505)

Subjects:

α-diversity indices of intestinal microbiota from healthy and diseased shrimp. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Heat map of intestinal microbiota from healthy and diseased shrimp at the genus level. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Taxa bar plot of intestinal microbiota from healthy and diseased shrimp at the family level. by Lalitphan Kitsanayanyong (19353505)

Subjects:

Shared intestinal microbiota between healthy and diseased shrimp. by Lalitphan Kitsanayanyong (19353505)

Subjects:

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The heart rate was similar among the groups. by Hongyu Li (1332669)

“…Following the overexpression of miRNA 221 in myocardium, there was a marked alleviation of myocardial injury and cardiomyocyte apoptosis and necrosis, significant enhancement of left ventricular systolic function, and marked decrease in the levels of PLB, p-PLB (Ser16), p-PLB (Thr17), caspase 3 and Cyt C, as well as a significant decrease in total calcium levels in myocardium.…”

S1 File - by Hongyu Li (1332669)

“…Following the overexpression of miRNA 221 in myocardium, there was a marked alleviation of myocardial injury and cardiomyocyte apoptosis and necrosis, significant enhancement of left ventricular systolic function, and marked decrease in the levels of PLB, p-PLB (Ser16), p-PLB (Thr17), caspase 3 and Cyt C, as well as a significant decrease in total calcium levels in myocardium.…”